St Jude Medical has won European clearance for the Ilumien Optis PCI Optimization System, technology designed to help treat coronary artery disease by modeling vessels and guiding stent placement.
St. Jude Medical's much-scrutinized defibrillator leads remained almost 100% safe from abrasion and mechanical failure after 5 years, according to an independent analysis, results the company hopes will quiet alarm from regulators and competitors.
Nanostim says its tiny wireless cardiac pacemaker has shown some success in its first three human patients, early signs that the potentially disruptive technology has legs. And the company's advance, presented this week at the Heart Rhythm Society meeting in Denver, may give it the lead over larger medical device rivals trying to come up with something similar.
St. Jude Medical gained a pivotal CE mark for two next-generation lines of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators, advancing in Europe even as its rivals win U.S. approval for competing devices.
Germany's Biotronik won the FDA's sign-off for its Ilesto line of cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D).
St. Jude Medical is kicking off a large-scale study of its Quadripolar Pacing System, aiming for FDA approval for a device the company says could improve outcomes for patients who don't respond to standard treatment.
St. Jude Medical ($STJ) scored European regulatory approval for a new quadripolar cardiac resynchronization therapy pacemaker. And with an immediate commercial rollout, the company gains another product that could help reverse sluggish revenue in the sector.
Johnson & Johnson, Abbott, St. Jude Medical and Quest Diagnostics are already experiencing new declines in demand for non-emergency medical devices and diagnostic tests. And that reality will likely spread to their competitors, Reuters reports. Blame the gradual ramp-up of the Affordable Care Act, which is likely to broaden the trend through much of the med tech industry in the months ahead.
St. Jude Medical's struggles continued in the new year, as declining demand for cardiac devices dragged sales down another 4%, but the company's cost-cutting helped it eke out some growth in net income.
St. Jude Medical won CE mark approval to use its deep-brain-stimulation devices to treat dystonia, making them the first implants cleared for the neurological movement disorder.